Vagif Ali Ogly Gasanov

Vagif Ali Ogly Gasanov

Auto-generated profile, based on publicly available information

Vagif Ali Ogly Gasanov

Koltsov Institute of Developmental Biology of Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2026 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
ALArthur Anatolievich Lee
Arthur Anatolievich Lee
DBD. О. Borisov
D. О. Borisov
VNV. S. Novikova
V. S. Novikova
DKDmitry Kashirskikh
Dmitry Kashirskikh
VKV. А. Khotina
V. А. Khotina
АVА. V. Vasilyev
А. V. Vasilyev
Objective: To calculate direct retail pharmacotherapy and monitoring costs for type 2 diabetes mellitus (T2DM) and obesity in adults in the Russian Federation based on the current Ministry of Health clinical guidelines. Material and methods. Using median retail prices from the apteka.ru and uteka.ru pharmacy aggregators in April 2026, costs for 14 T2DM and 5 obesity pharmacotherapy regimens were calculated. The dataset included 254 price items for T2DM drugs and 44 items for obesity drugs. The analysis was conducted from the patient out-of-pocket perspective. Direct non-drug medical monitoring costs, including laboratory tests, physician visits, and self-monitoring of blood glucose, were additionally assessed. Results. T2DM pharmacotherapy costs ranged from 175 to 14,716 rubles per month, corresponding to an approximately 84-fold difference between the least and most expensive regimens. Three cost strata were identified: (I) low-cost (12,000 rubles per month) strata. Low-cost regimens included metformin and its combinations with sulfonylureas; medium-cost regimens included dipeptidyl peptidase-4 inhibitors, sodium-glucose transport-2 inhibitors, insulin and injectable semaglutide; high-cost regimens included liraglutide, tirzepatide, and oral semaglutide. Obesity pharmacotherapy costs ranged from 2,958 rubles per month for sibutramine to 29,568 rubles per month for semaglutide (2.4 mg once a week). The total annual recommended monitoring costs including self-monitoring of blood glucose reached 32,900– 63,200 rubles for patients receiving oral therapy and 51,150–99,700 rubles for patients receiving insulin studies. Conclusion. Transition to modern pharmacotherapy regimens for T2DM and obesity is associated with a substantial increase in direct drug expenditure. Injectable semaglutide belongs to the medium-cost stratum, whereas oral semaglutide remains in the high-cost stratum, which may reflect the technological complexity of the oral salcaprozate sodium formulation and limited competition in this segment. Accounting for monitoring costs shows that the true direct financial burden on patients substantially exceeds drug costs, particularly in the low- and medium-cost strata. These data provide a basis for subsequent pharmacoeconomic analyses.

11 April 2026 in Journal of Clinical Practice
Verified
Journal Article
Open access
RIRoman V. Ishchenko
Roman V. Ishchenko
KGKirill Golubitskiy
Kirill Golubitskiy
Maksim SolopovMaksim Solopov
Maksim Solopov
IKIrina Kisilenko
Irina Kisilenko
MBMargarita Belotserkovskaya
Margarita Belotserkovskaya
VGVagif Ali Ogly Gasanov
Vagif Ali Ogly Gasanov
Wound infections, exacerbated by antibiotic resistance and biofilm formation, necessitate alternative therapeutic options. One promising approach is topical bacteriotherapy with live probiotics. The work aimed to summarize existing research on the multifaceted effects of live probiotics in infected wound healing. The review examines how probiotics directly influence pathogenic wound microflora by competing for adhesion sites and nutrients, secreting antagonistic compounds, altering the wound environment, and promoting co-aggregation. Probiotics’ antibiofilm activity is highlighted, including inhibition of quorum sensing systems and disruption of the extracellular biofilm matrix. Moreover, the review discusses the findings of in vitro and in vivo studies on the effects of live probiotics on macroorganisms. Probiotics have been shown to activate signaling pathways that regulate macrophage shift from a pro-inflammatory (M1) phenotype to a pro-repair (M2) phenotype, cytokine synthesis, keratinocyte and fibroblast migration and proliferation, angiogenesis, and collagen matrix formation. Thus, the multifaceted effects of probiotics cannot be replicated by metabolites or inactivated cells alone, highlighting the need for effective delivery systems for live probiotic cultures in infected wound management.

5 October 2026 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
ALArthur Anatolievich Lee
Arthur Anatolievich Lee
DBD. О. Borisov
D. О. Borisov
VNV. S. Novikova
V. S. Novikova
DKDmitry Kashirskikh
Dmitry Kashirskikh
VKV. А. Khotina
V. А. Khotina
АВА. В. Васильев
А. В. Васильев
Objective: To develop a three-tier approach to assessing the value of high-technology medicines, provide a rationale for the approach, and demonstrate its applicability using incretin-based therapy as an example. Material and methods. A conceptual study was carried out using a descriptive analysis of publicly available clinical, financial, investment, and regulatory data. The theoretical framework was based on approaches to broader health technology value assessment, including the ISPOR Value Flower and recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine. Sources were selected purposively; no systematic review was conducted. Results. A three-tier approach was proposed, including clinical value, value for the healthcare system, and an extended third tier divided into broader societal impacts of disease and treatment (3A) and the innovation and industrial impacts of pharmaceutical technology development and manufacturing (3B). By using incretin-based therapy as an example, the analysis showed that the expansion of indications and the market was accompanied by changes in corporate revenue structure, investment activity, and manufacturing infrastructure. In 2025, Mounjaro ® and Zepbound ® accounted for approximately 56% of Eli Lilly’s revenue, while glucagon-like peptide-1-based products for the treatment of type 2 diabetes and products for the treatment of obesity accounted for approximately 75.9% of Novo Nordisk’s revenue. Market capitalization, capital raised, and corporate revenue are not direct measures of clinical or societal value. Conclusion. A broader assessment of high-technology medicines requires separate consideration of their clinical, pharmacoeconomic, societal, and innovation and industrial impacts. Innovation and industrial impacts should not be incorporated directly into the calculation of the incremental cost-effectiveness ratio; instead, they should be presented as a separate analytical domain to inform industrial and science technology, and innovation policy.